Foundation Medicine, Inc.

Ucl Business Plc

Matthew J Hawryluk

Philip James Stephens

Doron Lipson

Vincent A Miller

Roman Yelensky

Garrett Michael Frampton

Timothy Robert Fenton

Chris Hendrik Boshoff

Matthias Alexander Lechner

Jeffrey S Ross

Alexander Nevin Parker

Siraj Mahamed Ali

Sean R Downing

Gary Palmer

Jie He

Michael Pellini

Mary Patricia Lancelotta

Mary Pat Lancelotta

Eric Karl Neumann

Ronald David Collette

Rachel Lauren Erbach

Helena Futscher De Deus

Alexander N Parker

Methods and compositions for treating cholangiocarcinoma.

Methods of treating cholangiocarcinoma

Novel RET fusion molecules and uses are disclosed.

KIF5B-RET fusion molecules and uses thereof

Provided are systems and methods for capturing outcome information associated with various cancer treatments. The system facilitates capture and analysis of cancer treatment information and associated outcome information. The treatment and outcome information can include genomic analysis and information on treatment of different cancers. The system can store and analyze any one or more of: tumor type, genomic alterations (e.g., genes and associated alterations, gene sequence mutations, alterations, amplifications, deletions, etc.), and treatment data (including, for example, treatments targeted to specific genes and/or genomic alterations). Users of the outcome system can supply and use the treatment and outcome information to facilitate diagnosis and therapy decisions. User interfaces within the system can be configured to allow users to easily locate outcome information associated with particular treatments of tumors having certain genomic alterations.

System and method for outcome tracking and analysis

Methods of treating a head and neck cancer are disclosed.

Human papilloma virus as predictor of cancer prognosis

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

NTRK1 fusion molecules and uses thereof

A system for tracking and analyzing cancer treatment and outcome information includes a user interface (UI) component for allowing selection of an alteration, an affected gene, an affected pathway, a tumor type, and/or a treatment; a processor configured to receive treatment information and outcome information associated with a patient population; organize the treatment information and the outcome information into at least one tuple; and generate outcome summary information; and an analysis component configured to compare a current patient record for a current patient to existing treatment information for the patient population, identify similar patients in the patient population based on information in the current patient record, and filter a grouping of similar patients; the processor is further configured to display, on the UI component, the outcome summary information; enable navigation within the treatment and outcome information; and identify, based on the outcome information, an appropriate treatment for the current patient.

Various embodiments provide interfaces to access genomic testing information and incorporate it into daily physician practice. According to one aspect, a graph-based data model is used that may be used to organizes and revise precision medicine knowledge. In one example structure, gene states are abstracted into alteration groups, where alteration groups are built using reverse engineering actionable information and storing that information within the graph-based data structure. Volumes of genomic alterations and associated information (e.g., journal articles, clinical trial information, therapies, etc.) are analyzed and synthesized into actionable information items viewable on an alteration system in a graph-based data format. According to one embodiment, the system can be configured to focus practitioners on discrete portions of the alteration information on which they can act. According to other aspects, curated information is provided on the system to enable practitioners to make informed decisions regarding the implications of the presence of specific genomic alterations.

System and method for managing genomic information

Methods of treating head and neck cancer

Novel RET fusion molecules and uses are disclosed. In one embodiment, a KIF5B-RET fusion includes an in-frame fusion of an exon of KIF5B (e.g., one or more exons encoding a kinesin motor domain or a fragment thereof) and an exon of RET (e.g., one or more exons encoding a RET tyrosine kinase domain or a fragment thereof). For example, the KIF5B-RET fusion can include an in-frame fusion of at least exon 15 of KIF5B or a fragment thereof (e.g., exons 1-15 of KIF5B or a fragment thereof) with at least exon 12 of RET or a fragment thereof (e.g., exons 12-20 of RET or a fragment thereof).

Methods and compositions for treating a urothelial and/or a micropapillary carcinoma, such as a micropapillary urothelial carcinoma are disclosed.

Growing community of inventors

Watertown, MA, United States of America

Matthew J Hawryluk